Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn’s disease

INTRODUCTION: Deep remission, defined as clinical remission with mucosal healing (MH), with anti-tumor necrosis factor (TNF)-α agents is a new target for therapy in Crohn’s disease (CD). Provided that the efficacy of infliximab (IFX) for induction of MH in CD has been demonstrated, there are much le...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Prz Gastroenterol
Glavni autori: Szymanska, Edyta, Dadalski, Maciej, Grajkowska, Wieslawa, Szymanska, Sylwia, Pronicki, Maciej, Kierkus, Jaroslaw
Format: Artigo
Jezik:Inglês
Izdano: Termedia Publishing House 2016
Teme:
Original Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5360663/
https://ncbi.nlm.nih.gov/pubmed/28337236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/pg.2016.64746
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items